Recombinant LAL alternatives by Hyglos - Endpoint Fluorescent Assays

True Innovation with Phage recombinant Technology and recombinant Horseshoe Crab Factor C

Highly specific and robust detection of endotoxin (LPS) helps you make confident in process control (IPC) and product release decisions:

  • Selecting the ideal endotoxin (LPS) test method for your samples
  • Removing inhibitory effects due to buffer and sample components
  • Improving reproducibility of results
  • Optimizing endotoxin recovery
  • Approved alternative methods - Recombinant Factor C (rFC)-based methods such as EndoZyme and EndoLISA are approved for use according to chapter 5.1.10 of the European Pharmacopoeia since July 1, 2016.


Endpoint fluorescence microplate assay based on recombinant Factor C (rFC), without solid phase, for the quantitative determination of endotoxins (lipopolysaccharides) in non-critical matrices such as process water and environmental samples. EndoZyme® offers excellent LPS-specificity, a very high test sensitivity (0.005 EU/ml) as well as a broad measurement range (0-50 EU/ml). Characterized by an excellent lot-to-lot consistency.

[Click here for EndoZyme® product & ordering information]

Endpoint fluorescence microplate assay with solid phase using a phage-derived capture molecule for the quantitative binding and determination of endotoxins (lipopolysaccharides). The world's first endotoxin detection system based on ELISA-technology overcoming limitations of traditional methods, such as the LAL (Limulus amebocyte lysate). A highly robust method with unprecedented salt and detergent tolerance. Developed and intended for complex sample matrices such as biopharmaceuticals; proteins, antibodies and vaccines.

[Click here for EndoLISA® product & ordering information]